Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Neisseria gonorrhoeae Infections Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Neisseria gonorrhoeae Infections Overview | 9 | 1 |
| Pipeline Products for Neisseria gonorrhoeae Infections Comparative Analysis | 10 | 1 |
| Neisseria gonorrhoeae Infections Therapeutics under Development by Companies | 11 | 1 |
| Neisseria gonorrhoeae Infections Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Neisseria gonorrhoeae Infections Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Neisseria gonorrhoeae Infections Products under Development by Companies | 16 | 1 |
| Neisseria gonorrhoeae Infections Products under Investigation by Universities/Institutes | 17 | 1 |
| Neisseria gonorrhoeae Infections Companies Involved in Therapeutics Development | 18 | 12 |
| Allergan Plc | 18 | 1 |
| BioDiem Ltd | 19 | 1 |
| Biolytics Pharma | 20 | 1 |
| Debiopharm International SA | 21 | 1 |
| F. Hoffmann-La Roche Ltd. | 22 | 1 |
| GlaxoSmithKline Plc | 23 | 1 |
| Merck &Co., Inc. | 24 | 1 |
| Paratek Pharmaceuticals, Inc. | 25 | 1 |
| Recce Pty Ltd | 26 | 1 |
| Redx Pharma Plc | 27 | 1 |
| Sarepta Therapeutics, Inc. | 28 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | 29 | 1 |
| Neisseria gonorrhoeae Infections Therapeutics Assessment | 30 | 9 |
| Assessment by Monotherapy Products | 30 | 1 |
| Assessment by Target | 31 | 2 |
| Assessment by Mechanism of Action | 33 | 2 |
| Assessment by Route of Administration | 35 | 2 |
| Assessment by Molecule Type | 37 | 2 |
| Drug Profiles | 39 | 47 |
| Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections Drug Profile | 39 | 1 |
| BDM-I Drug Profile | 40 | 2 |
| Biologic for Neisseria Gonorrhoeae Infection Drug Profile | 42 | 1 |
| dalbavancin Drug Profile | 43 | 10 |
| Debio-1453 Drug Profile | 53 | 1 |
| edodekin alfa SR Drug Profile | 54 | 1 |
| gepotidacin mesylate Drug Profile | 55 | 2 |
| Neisseria gonorrhoeae (virus like particle) vaccine Drug Profile | 57 | 1 |
| Neisseria gonorrhoeae vaccine Drug Profile | 58 | 1 |
| omadacycline tosylate Drug Profile | 59 | 6 |
| Recombinant Protein for Neisseria gonorrhoeae Infections Drug Profile | 65 | 1 |
| SM-295291 Drug Profile | 66 | 1 |
| SM-369926 Drug Profile | 67 | 1 |
| Small Molecule to Target Bacterial Cell Wall for Gonorrhoea and Tuberculosis Drug Profile | 68 | 1 |
| Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections Drug Profile | 69 | 1 |
| Small Molecules to Inhibit DNA Gyrase for Neisseria Gonorrhoeae Infections Drug Profile | 70 | 1 |
| Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections Drug Profile | 71 | 1 |
| Small Molecules to Inhibit Tubulin for Oncology and Neisseria Gonorrhoeae Infections Drug Profile | 72 | 1 |
| solithromycin Drug Profile | 73 | 12 |
| VT-12008911 Drug Profile | 85 | 1 |
| Neisseria gonorrhoeae Infections Dormant Projects | 86 | 1 |
| Neisseria gonorrhoeae Infections Discontinued Products | 87 | 1 |
| Neisseria gonorrhoeae Infections Product Development Milestones | 88 | 9 |
| Featured News &Press Releases | 88 | 1 |
| Dec 22, 2015: Cempra Enters Into a CRADA With the NIAID and Expands the Phase 3 Solithromycin Clinical Trial in Urogenital Gonorrhea to Include Additional Female Patients and Adolescents | 88 | 1 |
| Sep 10, 2015: Cempra to Present Data From Antibiotic Drug Solithromycin at ICAAC/ICC 2015 Meeting | 88 | 2 |
| Nov 19, 2014: Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies | 90 | 1 |
| Sep 09, 2014: Durata Therapeutics Presented Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) | 90 | 2 |
| Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection | 92 | 1 |
| Apr 26, 2013: Cempra To Present Data On Solithromycin's Potential Against Urogenital Infections And Multidrug-Resistant Pathogens At ECCMID | 92 | 2 |
| Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I | 94 | 1 |
| Mar 31, 2012: Cempra's Solithromycin Demonstrates In Vitro Activity Against Antibiotic-Resistant Neisseria Gonorrhoeae Isolates | 94 | 3 |
| Appendix | 97 | 2 |
| Methodology | 97 | 1 |
| Coverage | 97 | 1 |
| Secondary Research | 97 | 1 |
| Primary Research | 97 | 1 |
| Expert Panel Validation | 97 | 1 |
| Contact Us | 97 | 1 |
| Disclaimer | 98 | 1 |